17:04 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Otsuka's guadecitabine misses in Phase III for first-line AML

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) and its Astex Pharmaceuticals Inc. subsidiary said first-line treatment with guadecitabine (formerly SGI-110) missed the co-primary endpoints in the Phase III ASTRAL-1 trial to treat previously untreated acute myelogenous...
17:41 , Jul 31, 2018 |  BC Extra  |  Clinical News

Otsuka's guadecitabine misses in Phase III for first-line AML

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) and its Astex Pharmaceuticals Inc. subsidiary said first-line treatment with guadecitabine (formerly SGI-110) missed the co-primary endpoints in the Phase III ASTRAL-1 trial to treat previously untreated acute myelogenous...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
21:28 , Oct 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Gastric cancer Patient sample and mouse studies suggest inhibiting DNMT1 could help treat gastric cancer. In patients, high levels of DNMT1 in tumor samples were associated with disease progression and poor overall survival. In...
19:58 , Sep 21, 2017 |  BC Innovations  |  Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...
16:04 , Jun 7, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute lymphoblastic leukemia (ALL); acute myelogenous leukemia (AML); B cell lymphoma Cell culture and mouse studies identified an aminoquinoline-based dual DNMT1 / EHMT2 inhibitor that could help treat ALL, AML and diffuse large B...
22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
01:05 , Apr 21, 2017 |  BC Innovations  |  Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Clinical News

RX-3117: Phase Ib/IIa data

Data from 9 evaluable patients with relapsed or refractory metastatic pancreatic cancer in stage 1 of an open-label, U.S. Phase Ib/IIa trial showed that once-daily 700 mg oral RX-3117 given 5 times per week for...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Clinical News

Guadecitabine: Phase I/II started

Cancer Research UK began the double-blind, placebo-controlled, U.K. Phase I/II SPIRE trial to evaluate subcutaneous guadecitabine from Otsuka’s Astex Pharmaceuticals Inc. subsidiary plus cisplatin and gemcitabine. The first part will test escalating doses of guadecitabine...